A Single-arm, Open Phase II Trial of CAPOX Combined with Bevacizumab Combined with Tislelizumab in First-line Treatment of PDL1 CPS < 5 Locally Advanced or Metastati Gastroesophageal Adenocarcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

18 Mar 2025 Status changed from recruiting to completed.
29 Apr 2024 Planned End Date changed from 1 Oct 2023 to 1 Jun 2025.
29 Apr 2024 Planned primary completion date changed from 1 Apr 2023 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com